Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
Richard Quek1, Suzanne George2
1Visiting Fellow, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 2Clinical Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
Abstract: In the last decade a tremendous amount has been learned about the biology and treatment of gastrointestinal stromal tumor (GIST). Imatinib mesylate has revolutionized the treatment of metastatic GIST. In addition, the role of imatinib in localized GIST has gained much interest and may improve patient outcomes. Additionally, research efforts aimed at understanding the biology and the molecular heterogeneity of GIST both at initial presentation and at the time of resistance to imatinib, has helped guide rational approaches to treatment as well as future efforts aimed at treating imatinib-resistant GIST.
Keywords: gastrointestinal stromal tumors, GIST, review, imatinib, tyrosine kinase inhibitor, TKI
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.